News

In September 2007, Anesiva initiated a multicenter, randomized, double-blind, placebo-controlled Phase II trial to evaluate the safety and efficacy of a single 5 or 15mg dose of Adlea

The settlement provides for Bristol-Myers Squibb to make an initial payment of $5 million and to pay royalties on the US net sales of Orencia for any clinical

The data show substantially greater exposure to tizanidine from the oral spray (OS) formulations and earlier detectable plasma drug levels for OS doses versus the tablet (approximately 10

Fieldtests has also agreed to distribute company’s QuikSense Drugs-of-Abuse products through its distribution channels, and intends to add other QuantRx products, such as RapidSense and OralSense, as they

Presently, the company holds over 220 issued patents and pending patent applications world-wide, which cover novel agonists and antagonists of TLRs 7, 8 and 9. Steven Ritter, vice

The compound was designed to selectively inhibit the production of PCSK9 and could offer a new and complementary mechanism to current lipid-lowering therapies for the prevention and treatment

The Phase I clinical trial was a randomized, open-label, single dose, single center, two-period crossover trial designed to examine the safety, tolerability, pharmacokinetic and pharmacodynamic profile of the

AllerNase (triamcinolone acetonide) nasal spray, an aqueous based intranasal steroid is indicated for the once daily treatment of nasal symptoms associated with both seasonal and perennial allergic rhinitis

The company intends to spin off LifeHealthCare (LHC) by authorizing the issuance of one share of common stock of LHC for every share of common stock each stockholder